ArticleScientifica2012
B Cell in Autoimmune Diseases.
Article in Scientifica, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 1 synthesis or guideline pooled it, 197 citations in OpenAlex.
- Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.Rheumatology (Oxford, England) · 2024Pooled it
- FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus.Frontiers in immunology · 2022Trial
- Article
- IMMUND: A Diagnostic and Therapeutic Pipeline to Uncover the Convergence in Functional Perturbation at Early Stages of Neurodegenerative Diseases and Multiple Sclerosis Based on Protein Markers.International journal of molecular sciences · 2026Article
- Causal inference of metabolites in autoimmune liver diseases: A Mendelian randomization analysis.Medicine · 2026Article
- Connecting polygenic disease risk to cell states and regulatory programs through single-cell chromatin accessibility.bioRxiv : the preprint server for biology · 2026Article
- Single-cell immune transcriptomics reveals an inflammatory-inhibitory set-point spectrum in autoimmune diabetes.JCI insight · 2026Article
- Immunomodulatory and anti-inflammatory potential of S-nitrosoglutathione (GSNO) in multiple sclerosis: a review of mechanisms and therapeutic perspectives.Frontiers in immunology · 2026Review
- Quantitative systems pharmacology model of B cell immune response in mouse.Frontiers in immunology · 2026Article
- Genome-wide association study of atopic and autoimmune comorbidities in alopecia areata.Frontiers in immunology · 2026Article
- DDIT3 deficiency ameliorates systemic lupus erythematosus by regulating B cell activation and differentiation.Life medicine · 2025Article
- The B-cells paradigm in systemic sclerosis: an update on pathophysiology and B-cell-targeted therapies.Clinical and experimental immunology · 2025Review
- Immunophenotyping of Patients With Rheumatoid Arthritis Reveals Difference in CD27Mediators of inflammation · 2025Article
- Review
- Engineering antigen-presenting cells for immunotherapy of autoimmunity.Advanced drug delivery reviews · 2024Review
- New-onset Systemic Lupus Erythematosus Manifestation Following COVID-19: A Case Report and Literature Review.Internal medicine (Tokyo, Japan) · 2024Review
- Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.Journal of neurology · 2024Review
- Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors.Cancers · 2024Review
- Chemical immunology: Recent advances in tool development and applications.Cell chemical biology · 2024Review
- Suppression of B-Cell Activation by Human Cord Blood-Derived Stem Cells (CB-SCs) through the Galectin-9-Dependent Mechanism.International journal of molecular sciences · 2024Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The role of B cells in autoimmune diseases involves different cellular functions, including the well-established secretion of autoantibodies, autoantigen presentation and ensuing reciprocal interactions with T cells, secretion of inflammatory cytokines, and the generation of ectopic germinal centers. Through these mechanisms B cells are involved both in autoimmune diseases that are traditionally viewed as antibody mediated and also in autoimmune diseases that are commonly classified as T cell mediated. This new understanding of the role of B cells opened up novel therapeutic options for the treatment of autoimmune diseases. This paper includes an overview of the different functions of B cells in autoimmunity; the involvement of B cells in systemic lupus erythematosus, rheumatoid arthritis, and type 1 diabetes; and current B-cell-based therapeutic treatments. We conclude with a discussion of novel therapies aimed at the selective targeting of pathogenic B cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.